Trials / Terminated
TerminatedNCT05920408
Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours
A Phase 1B/2A Study to Assess the Safety, Tolerability, Pharmacokinetic and Anti-tumoral Activity of EXS21546 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Exscientia AI Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A phase 1B/2A study to assess the safety, tolerability, pharmacokinetic and anti-tumoral activity of EXS21546 in combination with a PD-1 inhibitor in patients with advanced solid tumours.
Detailed description
A phase 1B/2A study to assess the safety, tolerability, pharmacokinetic and anti-tumoral activity of EXS21546 in combination with a PD-1 inhibitor, nivolumab, in patients with advanced solid tumours, non small cell lung cancer and renal cell carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EXS21546 | EXS21546 Granule in Capsule |
Timeline
- Start date
- 2023-04-11
- Primary completion
- 2023-09-27
- Completion
- 2023-10-23
- First posted
- 2023-06-27
- Last updated
- 2023-11-08
Locations
5 sites across 2 countries: Belgium, France
Source: ClinicalTrials.gov record NCT05920408. Inclusion in this directory is not an endorsement.